Vanguard Group Inc. Has $5.57 Billion Stock Holdings in Becton, Dickinson and Company $BDX

Vanguard Group Inc. lifted its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 15.4% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 32,308,749 shares of the medical instruments supplier’s stock after buying an additional 4,305,947 shares during the period. Vanguard Group Inc. owned approximately 0.11% of Becton, Dickinson and Company worth $5,565,182,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Pinnacle Wealth Planning Services Inc. lifted its position in Becton, Dickinson and Company by 42.3% during the second quarter. Pinnacle Wealth Planning Services Inc. now owns 1,581 shares of the medical instruments supplier’s stock worth $272,000 after purchasing an additional 470 shares during the period. Nordwand Advisors LLC acquired a new position in shares of Becton, Dickinson and Company in the 2nd quarter valued at approximately $4,340,000. Chiron Capital Management LLC lifted its holdings in shares of Becton, Dickinson and Company by 662.4% during the 2nd quarter. Chiron Capital Management LLC now owns 10,704 shares of the medical instruments supplier’s stock worth $1,844,000 after acquiring an additional 9,300 shares during the period. Rothschild Investment LLC boosted its position in shares of Becton, Dickinson and Company by 10.5% during the 2nd quarter. Rothschild Investment LLC now owns 728 shares of the medical instruments supplier’s stock worth $125,000 after acquiring an additional 69 shares in the last quarter. Finally, Poehling Capital Management INC. bought a new position in Becton, Dickinson and Company in the second quarter valued at approximately $1,408,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Insider Buying and Selling

In other Becton, Dickinson and Company news, Director Bertram L. Scott sold 217 shares of the business’s stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $176.58, for a total transaction of $38,317.86. Following the sale, the director directly owned 35,816 shares of the company’s stock, valued at $6,324,389.28. The trade was a 0.60% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Claire Fraser sold 917 shares of the firm’s stock in a transaction on Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total transaction of $171,937.50. Following the transaction, the director directly owned 22,226 shares of the company’s stock, valued at $4,167,375. The trade was a 3.96% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 1,249 shares of company stock worth $231,358 over the last three months. Insiders own 0.36% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have weighed in on BDX shares. Piper Sandler cut their target price on Becton, Dickinson and Company from $200.00 to $190.00 and set a “neutral” rating for the company in a research note on Friday, November 7th. Wall Street Zen cut Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a report on Saturday, November 8th. Argus raised their price objective on Becton, Dickinson and Company from $220.00 to $230.00 in a research note on Monday, September 15th. Weiss Ratings reissued a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research note on Wednesday, October 8th. Finally, Morgan Stanley increased their target price on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an “overweight” rating in a report on Monday, August 11th. Three research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $203.27.

Becton, Dickinson and Company Trading Up 0.7%

NYSE BDX opened at $192.26 on Wednesday. The company has a market cap of $55.11 billion, a price-to-earnings ratio of 34.58, a price-to-earnings-growth ratio of 1.42 and a beta of 0.25. Becton, Dickinson and Company has a twelve month low of $162.29 and a twelve month high of $251.99. The company has a quick ratio of 0.62, a current ratio of 1.10 and a debt-to-equity ratio of 0.69. The business’s fifty day moving average is $186.68 and its 200 day moving average is $181.91.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 EPS for the quarter. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The firm had revenue of $5.32 billion during the quarter. As a group, sell-side analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, December 31st. Investors of record on Monday, December 8th will be given a dividend of $1.05 per share. The ex-dividend date is Monday, December 8th. This represents a $4.20 annualized dividend and a yield of 2.2%. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. Becton, Dickinson and Company’s dividend payout ratio is 72.04%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.